Diabetes community calls for quality standards for continuous glucose monitoring devices

The Lancet Regional Health - Europe 2026 Open access

Read full text
Authors: Francesco Giorgino, Tadej Battelino, Stefano Del Prato, Rahab Hashim, Sabine E. Hofer, Sufyan Hussain, Kasia Karpinska, Tom Melvin, Eric Renard, Campbell T. Hutton, Jannet Svensson, Bart Torbeyns
+2 more Petra Wilson, Chantal Mathieu
DOI: 10.1016/j.lanepe.2026.101598
Cited by: 2
References: 3

Abstract

Continuous Glucose Monitoring (CGM) devices are increasingly used by people living with diabetes (PwD) and contribute to a more personalised and effective diabetes care, leading to improved glycaemic control impacting diabetes-related complications. Their use is increasing in Europe, and many new manufacturers are coming to the market. CGMs, tracking in real-time glucose levels, are a key tool for PwD and their healthcare teams in the daily diabetes management. Besides tracking glucose changes in response to food, medication and physical activity, alerts are provided when hypoglycemia or hyperglycemia are imminent, allowing immediate intervention.

Fields of Study & Subjects

Diabetes Management and Research Hyperglycemia and glycemic control in critically ill and hospitalized patients Mobile Health and mHealth Applications

Publication details

Journal / source
The Lancet Regional Health - Europe
Publisher
Elsevier BV
Volume
62
Pages
101598–101598
Publication date
3 February 2026
Language
EN